Investor Relations News Releases News Releases September 16, 2021 Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 Additional Formats PDF Version September 3, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th Additional Formats PDF Version August 31, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 Additional Formats PDF Version August 12, 2021 Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version July 7, 2021 Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th Additional Formats PDF Version June 22, 2021 Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th Additional Formats PDF Version June 14, 2021 Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June Additional Formats PDF Version June 4, 2021 Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches Additional Formats PDF Version May 13, 2021 Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version May 11, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells Additional Formats PDF Version April 29, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings Additional Formats PDF Version April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
Investor Relations News Releases News Releases September 16, 2021 Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 Additional Formats PDF Version September 3, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th Additional Formats PDF Version August 31, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 Additional Formats PDF Version August 12, 2021 Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version July 7, 2021 Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th Additional Formats PDF Version June 22, 2021 Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th Additional Formats PDF Version June 14, 2021 Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June Additional Formats PDF Version June 4, 2021 Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches Additional Formats PDF Version May 13, 2021 Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version May 11, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells Additional Formats PDF Version April 29, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings Additional Formats PDF Version April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
News Releases September 16, 2021 Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 Additional Formats PDF Version September 3, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th Additional Formats PDF Version August 31, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 Additional Formats PDF Version August 12, 2021 Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version July 7, 2021 Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th Additional Formats PDF Version June 22, 2021 Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th Additional Formats PDF Version June 14, 2021 Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June Additional Formats PDF Version June 4, 2021 Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches Additional Formats PDF Version May 13, 2021 Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version May 11, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells Additional Formats PDF Version April 29, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings Additional Formats PDF Version April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version
September 16, 2021 Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4 Additional Formats PDF Version
September 3, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th Additional Formats PDF Version
August 31, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021 Additional Formats PDF Version
August 12, 2021 Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version
July 7, 2021 Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th Additional Formats PDF Version
June 22, 2021 Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th Additional Formats PDF Version
June 14, 2021 Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June Additional Formats PDF Version
June 4, 2021 Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches Additional Formats PDF Version
May 13, 2021 Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Additional Formats PDF Version
May 11, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells Additional Formats PDF Version
April 29, 2021 Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings Additional Formats PDF Version
April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version
March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version
March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version
March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version
February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version
February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version
February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version
January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version
January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version
January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version
November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version
November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version
October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version
